On October 31, we said Viking Therapeutics (SYM: VKTX) was a solid opportunity.
Especially as the company was set to jump into Obesity Week where the company was presenting results from its Phase 2 VENTURE clinical trial with its subcutaneous formulation of VK2735. It’s other presentation will highlight results from its Phase 1 multiple ascending dose clinical trial of its oral formulation of VK2735.
Yesterday morning, the stock was up about $6 a share after VKTX showed strong results for its experimental obesity pill, with increased weight loss observed at higher doses.
“Patients on 100-milligram doses of Viking’s VK2735 lost an average of 8.2% of their body weight after 28 days in an early-stage study, or 6.8% more than those taking a placebo, the company said in a presentation at the Obesity Week meeting Sunday in San Antonio,” added Seeking Alpha.
Plus, the company is about to start its Phase 2 study of the oral version of VK2735 before the end of the year. “The oral version is being developed as an alternative for patients hesitant for injection-based therapy, looking to maintain their weight loss, or transition away from the injectable version of VK2735.”
Moving forward, we’d like to see VKTX closer to $100 a share.
